William Scott Durall - 22 Jul 2025 Form 3 Insider Report for CARLSMED, INC.

Role
Chief Commercial Officer
Signature
/s/ Leonard Greenstein, as attorney-in-fact, for William Scott Durall
Issuer symbol
CARL on Nasdaq
Transactions as of
22 Jul 2025
Net transactions value
$0
Form type
3
Filing time
22 Jul 2025, 17:28:51 UTC
Previous filing
08 May 2023
Next filing
30 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Durall William Scott Chief Commercial Officer C/O CARLSMED, INC., 1800 ASTON AVE., SUITE 100, CARLSBAD /s/ Leonard Greenstein, as attorney-in-fact, for William Scott Durall 22 Jul 2025 0001818744

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CARL Stock Option (Right to Buy) 22 Jul 2025 Common Stock 89,606 $2.23 Direct F1, F3
holding CARL Stock Option (Right to Buy) 22 Jul 2025 Common Stock 134,973 $4.35 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 89,606 unvested stock options convertible into approximately 89,606 shares of the Issuer's common stock, which began to vest on September 3, 2024, subject to a one-year cliff, and will be fully vested on September 3, 2028. These options are reported after giving effect to the 1-for-5.58 reverse split of the Issuer's common and preferred stock effected on July 10, 2025 (the "Reverse Split").
F2 Includes 134,973 unvested stock options convertible into approximately 134,973 shares of the Issuer's common stock, which began to vest on December 15, 2024, subject to a one-year cliff, and will be fully vested on December 15, 2028. These options are reported after giving effect to the Reverse Split.
F3 The exercise price has been adjusted to reflect the Reverse Split.